Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07121244 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer
A Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer, sponsored by Radionetics Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 7
- Study locations
NCT07121244 is a Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer that is actively recruiting participants, run by Radionetics Oncology. The registered enrollment target is 62 participants. The trial reports 7 study locations across 7 states.
The verdict
NCT07121244, a Phase 1 study of Locoregionally Recurrent Hormone-receptor Positive Breast Cancer and Metastatic Hormone Receptor Positive Breast Cancer, is actively recruiting participants, sponsored by Radionetics Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 7
- Study locations
Study Summary
A phase 1 study of 68Ga-R11228 and 177Lu-R11228 in breast cancer.
Conditions Studied
Interventions
- DRUG 68Ga-R11228
- DRUG 177Lu-R11228
Study Locations (7)
Indiana
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
Maryland
- United Theranostics - Glen Burnie
New Jersey
- United Theranostics Princeton - Princeton
Ohio
- University Hospital Seidman Cancer Center - Cleveland
Texas
- MD Anderson Cancer Center - Houston
Utah
- University of Utah - Huntsman Cancer Institute - Salt Lake City
Other
- Melbourne Theranostic Innovation Centre (MTIC) - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2033-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07121244
The ClinicalTrials.gov registry entry for NCT07121244 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radionetics Oncology, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Locoregionally Recurrent Hormone-receptor Positive Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which 68Ga-R11228 is the first listed.
NCT07121244 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Indiana, Maryland, New Jersey.
Frequently Asked Questions
What is clinical trial NCT07121244 about?
NCT07121244 is a clinical study titled "A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer". A phase 1 study of 68Ga-R11228 and 177Lu-R11228 in breast cancer.
What is the current status of trial NCT07121244?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2025-10-01. Estimated completion is 2033-06-01.
What conditions does trial NCT07121244 study?
This clinical trial studies the following conditions: Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer.
What interventions are being tested in trial NCT07121244?
The interventions under investigation include: 68Ga-R11228 (DRUG), 177Lu-R11228 (DRUG).
Who is sponsoring clinical trial NCT07121244?
This trial is sponsored by Radionetics Oncology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07121244 being conducted?
This trial has 7 study locations across Indiana, Maryland, New Jersey, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
All registered trials for this condition
Metastatic Hormone Receptor Positive Breast Cancer
All registered trials for this condition
Indiana
All trials with a study site in Indiana
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.